During the last three months, the FDA approved several molecules and indications. In May, the following indications were approved: Fam-trastuzumab...
Pfizer
Voxelotor (Oxbryta) is the first hemoglobin oxygen-affinity modulator. It has disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators...
Pfizer has agreed to acquire Global Blood Therapeutics for $5.4 billion. Based on this, Global Blood Therapeutics will hand its...
